TTT20171 is a SDHC inhibitor. TTT20171 exhibits nanomolar inhibition of CII but lacks cellular potency. In cell assays, the most sensitive cells (22Rv1 prostate cancer cells) are inhibited at an IC50=5.4 uM, a value well above the suggested use concentration of 2 uM and the criterion of 1 uM for a quality chemical probe. References: Wang H, Huwaimel B, Verma K, Miller J, Germain TM, Kinarivala N, Pappas D, Brookes PS, Trippier PC. Synthesis and Antineoplastic Evaluation of Mitochondrial Complex II (Succinate Dehydrogenase) Inhibitors Derived from Atpenin A5. ChemMedChem. 2017 Jul 6;12(13):1033-1044. doi: 10.1002/cmdc.201700196. Epub 2017 Jun 12. PubMed PMID: 28523727; PubMed Central PMCID: PMC5557372.

纯度：≥98%

CAS：2110408-47-2